BEDFORD, Mass., March 14, 2016 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced total worldwide sales in 2015 of $773 M US (€686 M). In its two major business segments, Hemostasis and Critical Care Diagnostics, IL achieved significant worldwide growth of 8.4% and 5%, respectively, in local currencies. Most significantly, IL achieved double-digit Hemostasis growth in each of the top three worldwide markets, US, China, and Japan. Additionally, IL achieved above-market growth in all key territories, including Europe. IL, an integral part of the Wefen family of companies, develops and manufactures Hemostasis and Critical Care Diagnostic products, distributed by Werfen organizations around the globe.
Contributing to the success of IL in 2015 was the Company's record number of ACL TOP® Hemostasis Testing Systems and GEM® Premier™ 4000 Critical Care Systems shipped to customers globally; record sales of HemosIL® reagents and GEM Premier cartridge PAKs; and significant new business contracts signed with large Group Purchasing Organizations, lab networks, and regional hospital consortiums throughout the world.
"2015 was an unprecedented year for innovation at IL. Our new ACL TOP Family 50 Series Hemostasis Testing Systems were successfully introduced in Europe, Japan and other international territories, and we have received 510(k) clearance from the US FDA. This will help us continue to expand our #1 position in the global Hemostasis laboratory market," said Ramon Benet, CEO at IL. "In Critical Care, we accomplished significant milestones with our new generation GEM Premier system, providing the foundation for commercial activities in selected territories this year. Overall, we are very proud of our contribution to the efforts of customers as they strive to enhance efficiency, reduce costs and improve the quality of patient care."
While sales of the Company's flagship GEM Premier 4000 system achieved record levels in 2015, GEM Premier 3000/3500 systems continued to grow steadily throughout the world. These systems feature Intelligent Quality Management (iQM®), the first and only automated, active total quality management system. In addition, GEMweb® Plus 300/400 Custom Connectivity software, a significant asset in the Company's success, offers lab managers complete control of their analyzers from any PC or GEM Premier system, operator certification and advanced regulatory management capabilities.
In Hemostasis diagnostics, the ACL TOP Family remains the most advanced and successful Hemostasis testing platform in the world today. New ACL TOP Family 50 Series Systems represent a true breakthrough in Hemostasis Quality Management for routine and specialty testing, offering unprecedented pre-analytical quality assurance, risk- management and laboratory accreditation benefits. The new systems further strengthen the IL franchise and reinforce the Company's leadership position in Hemostasis diagnostics.
In August 2015, IL announced their exclusive worldwide distributor agreement with Thermo Fisher Scientific to create a unique, state-of-the-art Hemostasis Work Cell, HemoCell™ Specialized Lab Automation, connecting ACL TOP 700/750 systems to the Thermo Scientific™ TCAutomation™ Laboratory Automation System. Hemostasis labs can now standardize their testing processes to manage heavy workloads with tailored automated solutions from the leaders in Hemostasis and automation.
Additionally, the ACL AcuStar® system, the first chemiluminescent immunoassay analyzer, continues to deliver full automation to Specialty Hemostasis testing. Complementing the Company's Hemostasis instrument portfolio is their complete line of HemosIL® general screening and specialty testing assays for the diagnosis and management of bleeding and thrombotic disorders. In 2015, IL introduced novel reagents, including HemosIL Rivaroxaban Testing Solution in Europe and other international territories. The HemosIL Liquid Anti-Xa assay, when used in conjunction with HemosIL Rivaroxaban Calibrators and HemosIL Rivaroxaban controls offers an automated solution for measurement of the direct oral anticoagulant, rivaroxaban (Xarelto®).
Instrumentation Laboratory (www.instrumentationlaboratory.com), founded in 1959, is an integral part of the Wefen family of companies. IL is a worldwide developer and manufacturer of in vitro diagnostic instruments, related reagents and controls, and information management systems for Hemostasis and Critical Care testing. IL products are distributed to hospitals and independent clinical laboratories by Werfen organizations around the globe. IL GEM® product offerings, part of the Critical Care line, include GEM Premier 4000, GEM Premier 3500 and GEMweb® Plus Custom Connectivity. The IL Hemostasis portfolio includes new ACL TOP® Family 50 Series Hemostasis Testing Systems, fully automated, high-productivity analyzers, with pre-analytical sample quality assurance, comprised of ACL TOP 750/CTS/LAS, ACL TOP 550 CTS and ACL TOP 350 CTS, in addition to the original ACL TOP Family of systems. IL also offers the ACL AcuStar®, ACL ELITE®, and other Hemostasis analyzers, along with the comprehensive HemosIL® line of reagents. New HemoCell™ Specialized Lab Automation connects ACL TOP 700/750 systems to the Thermo Scientific™ TCAutomation™ Laboratory Automation System to create a unique, specialized work cell. IL is based in Bedford, Massachusetts.
The Instrumentation Laboratory logo, GEM, GEMweb, iQM, HemosIL, ACL TOP, ACL ELITE, ACL AcuStar, HemoCell and Premier are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions. All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/instrumentation-laboratory-reports-record-worldwide-sales-in-2015-300234860.html
SOURCE Instrumentation Laboratory